No single bacterium directly causes rheumatoid arthritis, but several species are now strongly linked to triggering the autoimmune process that leads to it. The most studied are two oral bacteria associated with gum disease and a gut bacterium that appears overrepresented in people with new-onset RA. Each works through a different mechanism, but they share a common thread: they can confuse the immune system into attacking the body’s own joint tissue.
The Gum Disease Connection
The strongest bacterial link to rheumatoid arthritis involves Porphyromonas gingivalis, a bacterium responsible for chronic gum disease. This microbe has a unique ability that sets it apart from nearly all other bacteria: it produces an enzyme that chemically modifies human proteins through a process called citrullination. Normally, your immune system recognizes your own proteins and leaves them alone. But citrullinated proteins look foreign, prompting the immune system to produce antibodies against them. These antibodies, known as ACPAs (anti-citrullinated protein antibodies), are found in roughly 60 to 70 percent of RA patients and can appear in the blood years before joint symptoms start.
The clinical evidence reinforces this connection. RA patients with gum disease have significantly higher ACPA levels than those without it, and the severity of gum disease correlates with antibody levels. In one study, patients who received periodontal treatment at the same time they started RA therapy showed significantly greater improvement in disease activity at three months compared to those who delayed dental care. Patients with higher baseline antibody levels against P. gingivalis also responded better to RA treatment over 12 months, suggesting the bacterial burden directly influences how well the disease can be controlled.
A Second Oral Bacterium With a Different Trick
Aggregatibacter actinomycetemcomitans, another gum disease bacterium, works through a completely different mechanism. It produces a toxin called leukotoxin A that attacks neutrophils, a type of white blood cell. When neutrophils encounter this toxin, they undergo a burst of hypercitrullination, flooding the area with the same modified proteins that trigger ACPA production. Antibodies against leukotoxin A are elevated in RA patients and correlate with ACPA levels, adding another line of evidence that the mouth may be where the autoimmune process begins for many people.
This gives researchers two independent pathways from the gums to the joints: one bacterium that directly modifies proteins, and another that forces immune cells to do it themselves. Both lead to the same result, a growing pool of citrullinated proteins that train the immune system to attack similar structures in joint tissue.
The Gut Bacterium Found in Early RA
Prevotella copri, a bacterium that lives in the intestines, shows a striking pattern in people newly diagnosed with RA. It was detected in the stool of 50 percent of patients with new-onset, untreated RA compared to just 20 percent of healthy individuals. This bacterium produces a protein that resembles a stress-response protein found in human joints, which may activate immune cells that then cross-react with joint tissue.
More broadly, people with RA have measurably less diverse gut microbiomes than healthy individuals, with the degree of reduced diversity correlating with disease duration and autoantibody levels. The differences are most pronounced among rare and less abundant bacterial species, suggesting that losing certain protective microbes may matter as much as gaining harmful ones.
Molecular Mimicry: When Bacterial Proteins Resemble Joint Tissue
Beyond the citrullination pathway, several bacteria appear to trigger RA through molecular mimicry, where bacterial proteins share amino acid sequences with human joint proteins. The immune system attacks the bacterium, then mistakenly turns on the body’s own tissue that looks similar. Proteus mirabilis, a common urinary tract bacterium, is one of the best-studied examples. Its hemolysin protein shares a sequence with a region on immune system molecules strongly associated with RA susceptibility. Its urease enzyme resembles a segment of type XI collagen found in cartilage, and antibodies against this bacterial enzyme cross-react with the human protein.
The list extends further. Escherichia coli, Klebsiella pneumoniae, and several Streptococcus species all produce a protein (L-asparaginase) that shares a sequence with an immunologically important segment of type II collagen, the main structural protein in cartilage. Immune cells from RA patients respond to both the bacterial and human versions of this sequence, and exposure to the bacterial protein can activate these cells and drive inflammation. Even Epstein-Barr virus, while not a bacterium, uses a similar mimicry mechanism and is often discussed alongside these bacterial triggers.
Why No Single Bacterium Is “The Cause”
Rheumatoid arthritis requires a combination of genetic susceptibility, environmental triggers, and immune dysregulation. Bacteria appear to act as triggers in people who are already predisposed. Someone carrying certain genetic variants (particularly in HLA-DR genes) has an immune system that is more likely to react to citrullinated proteins or to be fooled by molecular mimicry. Add a chronic bacterial exposure, whether from untreated gum disease, a gut microbiome shift, or recurrent infections, and the autoimmune cascade can begin.
This explains why not everyone with gum disease develops RA, and not every RA patient has gum disease. The bacteria provide one piece of a multi-step puzzle. But the evidence is strong enough that managing oral health has become a practical consideration in RA care. Treating periodontal disease alongside standard RA therapy produces better outcomes than treating RA alone, particularly in the early months after diagnosis.
Can Antibiotics Treat RA?
Given the bacterial connections, researchers have tested whether antibiotics could improve RA. Three placebo-controlled trials of minocycline showed significant improvement in clinical and laboratory measures compared to placebo. Doxycycline has also been shown to enhance the response to methotrexate, a standard RA medication. However, a trial of combination intravenous and oral antibiotics showed only modest results, with just 2 out of 12 patients in the treatment group achieving meaningful improvement compared to none in the placebo group.
The limited success of antibiotics makes sense given what we know. By the time RA is diagnosed, the autoimmune process is self-sustaining. Killing the bacteria that initially triggered it doesn’t switch off the immune response. This is why the most promising practical intervention isn’t antibiotics but periodontal care: reducing the ongoing bacterial load that continues to generate citrullinated proteins and fuel the immune system’s misdirected attack on the joints.